← 15 October 2026's Current Affairs · Science & Tech GA Prelims ★★★☆☆ Mains ★★☆☆☆
DR Congo Ebola vaccine trial to begin within weeks, says WHO
ಸುದ್ದಿಯಲ್ಲಿ ಏಕೆ?
An Ebola vaccine for one strain, tested on another: the Ervebo cross-protection trial GS-III Science and Health tests
The WHO says a full-scale human trial will begin within weeks in the Democratic Republic of the Congo to test whether Ervebo gives cross-protection against Bundibugyo ebolavirus. Ervebo is a vaccine approved for use against the more common Zaire strain of Ebola.
Why it matters: general awareness
What you need to know
2 ನಿಮಿಷ
The WHO says a full-scale human trial will begin within weeks in the Democratic Republic of the Congo to test whether Ervebo gives cross-protection against Bundibugyo ebolavirus.
Ervebo is a vaccine approved for use against the more common Zaire strain of Ebola.
ಮೂಲಗಳು: Topper IAS editorial (PIB / The Hindu / Indian Express)
ಮುಖ್ಯ ಅಂಶಗಳು
Remember these
- WHO says a full-scale human trial will begin within weeks in the Democratic Republic of the Congo
- The trial will test whether Ervebo gives cross-protection against Bundibugyo ebolavirus
- Ervebo is approved for use against the Zaire strain of Ebola, the more common strain
- Bundibugyo ebolavirus is a different Ebola species from Zaire ebolavirus
- WHO is the UN specialised agency for global health, headquartered in Geneva
ಪ್ರಿಲಿಮ್ಸ್ · ಮೇನ್ಸ್
How the exam will ask it
ಪ್ರಿಲಿಮ್ಸ್
- Ervebo is a vaccine approved against the Zaire strain of Ebola virus.
- Cross-protection means a vaccine against one strain may also protect against a related strain; the DRC trial will test this for Bundibugyo ebolavirus.
- Ebola is a viral haemorrhagic fever caused by viruses of the genus Orthoebolavirus, with several distinct species including Zaire and Bundibugyo.
- The Democratic Republic of the Congo is the site of the planned WHO-announced human trial.
ಮೇನ್ಸ್
GS-III (Science and Technology, health) and GS-II (international organisations). Issue: vaccines exist for only one Ebola species, leaving outbreaks of other strains such as Bundibugyo without a licensed vaccine. Policy: WHO-coordinated trials in affected countries test whether an approved vaccine gives cross-protection. Implication and way forward: faster ring-vaccination readiness, stronger surveillance and equitable access to vaccines, with India building its own outbreak preparedness and research capacity.
Quick recall
Answer before you reveal
ಎಬೋಲಾ ಲಸಿಕೆ ಎರ್ವೆಬೊ (Ervebo) ಕುರಿತು ಈ ಕೆಳಗಿನ ಹೇಳಿಕೆಗಳನ್ನು ಪರಿಗಣಿಸಿ:
- ಇದು ಎಬೋಲಾದ ಝೈರ್ ತಳಿಯ ವಿರುದ್ಧ ಬಳಕೆಗೆ ಅನುಮೋದಿತವಾಗಿದೆ.
- ಇದು ಈಗಾಗಲೇ ಬುಂಡಿಬುಗ್ಯೊ ತಳಿಯ ವಿರುದ್ಧ ಅನುಮೋದಿತವಾಗಿದೆ. ಮೇಲಿನ ಹೇಳಿಕೆಗಳಲ್ಲಿ ಯಾವುದು/ಯಾವವು ಸರಿ?
- 1 ಮಾತ್ರ
- 2 ಮಾತ್ರ
- 1 ಮತ್ತು 2 ಎರಡೂ
- 1 ಅಥವಾ 2 ಯಾವುದೂ ಅಲ್ಲ
ಉತ್ತರ ನೋಡಿ
ಉತ್ತರ: A — ಹೇಳಿಕೆ 1 ಮಾತ್ರ ಸರಿ. ಎರ್ವೆಬೊ ಝೈರ್ ತಳಿಯ ವಿರುದ್ಧ ಅನುಮೋದಿತ; ಡಿಆರ್‌ಸಿಯಲ್ಲಿ ನಡೆಯಲಿರುವ ಪ್ರಯೋಗವು ಬುಂಡಿಬುಗ್ಯೊ ವಿರುದ್ಧ ಅದು ಅಡ್ಡ-ರಕ್ಷಣೆ ನೀಡುತ್ತದೆಯೇ ಎಂದು ಪರೀಕ್ಷಿಸುತ್ತದೆ.
Convert this topic into marks
Today's 10-MCQ test · instant analysis · Powered by AdaptIQ